Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?

Fuente: Wiley Open Access
Saved in:
Bibliographic Details
Main Authors: María A. Rodríguez‐Santiago, Valerie Wojna, Eric Miranda‐Valentín, Steven Arnold, Vanessa Sepúlveda‐Rivera
Format: Artículo Open Access
Published: Wiley 2024
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867007545415041024
author María A. Rodríguez‐Santiago
Valerie Wojna
Eric Miranda‐Valentín
Steven Arnold
Vanessa Sepúlveda‐Rivera
author_facet María A. Rodríguez‐Santiago
Valerie Wojna
Eric Miranda‐Valentín
Steven Arnold
Vanessa Sepúlveda‐Rivera
María A. Rodríguez‐Santiago
Valerie Wojna
Eric Miranda‐Valentín
Steven Arnold
Vanessa Sepúlveda‐Rivera
collection Wiley Open Access
contents Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease? María A. Rodríguez‐Santiago Valerie Wojna Eric Miranda‐Valentín Steven Arnold Vanessa Sepúlveda‐Rivera Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring AbstractTypically, Alzheimer's disease (AD) diagnosis is not made at its earliest period, for instance, at mild cognitive impairment (MCI) and early AD (E‐AD). Our study aims to demonstrate a correlation between the screening tools, including the Mini‐Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Clinical Dementia Rating (CDR), and the biological biomarkers in the cerebrospinal fluid (CSF) amyloid beta 1‐42 (Aβ42), phosphorylated tau (p‐tau) proteins and total tau (t‐tau)/Aβ42 ratio in Puerto Ricans > 55 years old with MCI and E‐AD. We evaluated 30 participants, including demographics, memory scales, and CSF biomarkers. Twenty‐eight CSF biomarkers (Aβ42, p‐tau protein, and t‐tau/Aβ42 ratio) were analyzed using the Meso Scale Discovery Platform (MSD). Associations between memory scales (MoCA, MMSE, CDR) and CSF markers were performed using Spearman rho correlation. Our study revealed a statistical association favoring a direct relationship between MMSE and MoCA with t‐tau/Aβ42 ratio in CSF (P = 0.022, P = 0.035, respectively). We found a trend toward significance with an inverse relationship with MMSE and Aβ42 (P = 0.069) and a direct relationship with MMSE and p‐tau (P = 0.098). MMSE and MoCA screening tests were identified with a statistically significant association with the CSF biomarkers, specifically t‐tau/Aβ42 ratio, in elderly Puerto Ricans with MCI and E‐AD. Puerto Ricans > 55 years old with MCI and E‐AD could be screened confidently with MMSE and MoCA for a higher likelihood of earlier detection and, thus, initiation of disease‐modifying treatment and prompt non‐pharmacological interventions. 10.1002/dad2.12554 http://creativecommons.org/licenses/by-nc-nd/4.0/
doi_str_mv 10.1002/dad2.12554
format Artículo Open Access
id wiley_oa_10_1002_dad2_12554
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?
María A. Rodríguez‐Santiago
Valerie Wojna
Eric Miranda‐Valentín
Steven Arnold
Vanessa Sepúlveda‐Rivera
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease? María A. Rodríguez‐Santiago Valerie Wojna Eric Miranda‐Valentín Steven Arnold Vanessa Sepúlveda‐Rivera Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring AbstractTypically, Alzheimer's disease (AD) diagnosis is not made at its earliest period, for instance, at mild cognitive impairment (MCI) and early AD (E‐AD). Our study aims to demonstrate a correlation between the screening tools, including the Mini‐Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Clinical Dementia Rating (CDR), and the biological biomarkers in the cerebrospinal fluid (CSF) amyloid beta 1‐42 (Aβ42), phosphorylated tau (p‐tau) proteins and total tau (t‐tau)/Aβ42 ratio in Puerto Ricans > 55 years old with MCI and E‐AD. We evaluated 30 participants, including demographics, memory scales, and CSF biomarkers. Twenty‐eight CSF biomarkers (Aβ42, p‐tau protein, and t‐tau/Aβ42 ratio) were analyzed using the Meso Scale Discovery Platform (MSD). Associations between memory scales (MoCA, MMSE, CDR) and CSF markers were performed using Spearman rho correlation. Our study revealed a statistical association favoring a direct relationship between MMSE and MoCA with t‐tau/Aβ42 ratio in CSF (P = 0.022, P = 0.035, respectively). We found a trend toward significance with an inverse relationship with MMSE and Aβ42 (P = 0.069) and a direct relationship with MMSE and p‐tau (P = 0.098). MMSE and MoCA screening tests were identified with a statistically significant association with the CSF biomarkers, specifically t‐tau/Aβ42 ratio, in elderly Puerto Ricans with MCI and E‐AD. Puerto Ricans > 55 years old with MCI and E‐AD could be screened confidently with MMSE and MoCA for a higher likelihood of earlier detection and, thus, initiation of disease‐modifying treatment and prompt non‐pharmacological interventions. 10.1002/dad2.12554 http://creativecommons.org/licenses/by-nc-nd/4.0/
title Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?
topic Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
url https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.12554